Phase 1 study of concomitant tumor treating fields and temozolomide chemoradiation for newly diagnosed glioblastoma
Samuel Goldlust(Hackensack University Medical Center), George J. Kaptain(Hackensack University Medical Center), Hooman Azmi(Hackensack University Medical Center), Samuel Singer(Memorial Sloan Kettering Cancer Center), Lori Cappello(Hackensack University Medical Center), Kangmin D. Lee(Hackensack University Medical Center), Brett E. Lewis(Hackensack University Medical Center), Anthony C Ingenito(Hackensack University Medical Center), Ahmad Kareem Almekkawi(Brigham and Women's Hospital), Themba Nyirenda(Hackensack University Medical Center)
Cited by 3
Related Papers
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
|Nature Genetics|2013|818
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
|Oncogene|2001|700
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
|American Journal Of Pathology|2000|647